Quantum Genomics extends its collaboration agreement with its partner in animal health | Bourse Reflex
Accueil > Actualités > Communiqués

€ 6.4  -2.59%
AJOUTER À : Mon Portefeuille | Ma Liste | Mes alertes

Quantum Genomics extends its collaboration agreement with its partner in animal health

Mardi 28 Jun 2016 à 18:00

Companies to continue joint development of therapies to treat heart failure in dogs
 

Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced that it has extended its collaboration agreement with its partner, a world leader in animal health.

Under this agreement, the two companies will continue working together to initiate additional clinical trials of the drug candidate developed by Quantum Genomics for the treatment of heart failure in dogs. The specific FINANCIAL terms of the contact remain undisclosed.

Lionel Segard, Quantum Genomics' President and Chief Executive Officer, commented:

“The goal of this partnership is to overcome heart failure challenges in dogs. We are pleased to extend our collaboration with a major player in the industry and continue the evaluation of veterinary applications for our unique therapeutic candidates. We believe such collaborative veterinary clinical development efforts will further strengthen our position in the field of heart failure, at a time when we are launching our Phase IIa trial in humans.”
 

CONTACTS
Quantum Genomics

Lionel Ségard
Chairman & Chief Executive Officer
+33 1 85 34 77 77
 
Quantum Genomics
Marc Karako
CFO – Investor Relations
+33 1 85 34 77 75
marc.karako@quantum-genomics.com
 
ACTUS finance et communication (Europe)
Jean-Michel Marmillon
Press Relations
+33 1 53 67 36 73
jmmarmillon@actus.fr
 
The Ruth Group (U.S.)
Lee Roth / Kirsten Thomas
Investor / Public Relations
+1 646-536-7012 / +1 508-280-6592

 

ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially hypertension and heart failure.
The Company is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (isin code FR0011648971, Ticker ALQGC).
The Company has offices in Paris, France, and New York, NY, USA. For more information, please visit www.quantum-genomics.com.
 


Partager sur Facebook
Article Précédent :
Compte-rendu de l'Assemblée...
Article Suivant :
Communiqué sur les résultats...

Ecrire un commentaire

J'accepte la charte et que mon commentaire soit publié sur BourseReflex.com 

Les autres actualités


Retour vers 'Communiqués' »




Mots-clés : New york   Usa   Genomics   Extends   Health   Companies   Heart   Failure   Dogs   Alqgc   Developing   Unmet   Field   Clinical   Lionel   Segard  
Sociétés citées dans cette news : FINANCIAL   QUANTUM GENOMICS   Quantum Genomics  

Si vous passez un ordre de bourse sur le CAC40 le vendredi soir à 18h, quand sera t-il éxécuté?
Mon portefeuille virtuel

Initiez-vous à la gestion gratuitement et sans risque !

Ma liste de valeurs

Suivez l'évolution du cours de vos valeurs préférées !

Alerte email

Soyez immediatement informés


Retrait de Borloo
Jean-Louis Borloo a décidé de ne pas se porter candidat à l'élection présidentielle de 2012. Qu'en pensez-vous?